Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends
Journal of the European Academy of Dermatology and Venereology · 2026
DOI: 10.1111/jdv.20522 ↗At a glance
Journal article in Journal of the European Academy of Dermatology and Venereology, 2026. Written by Yodit Girmay and 5 co-authors. Institution: Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Melanoma, Skin Neoplasms. Cited 2 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Cancer Research Funds of Radiumhemmet, Region Stockholm, Cancerfonden.
Abstract (original language)
Background
Desmoplastic melanoma (DM) is a rare subtype, accounting for less than 5% of primary cutaneous invasive melanomas. DM often arises in chronically sun‐exposed skin, in older individuals. While the incidence of cutaneous melanoma has increased globally, trends specific to DM are less documented and studies on survival outcomes for DM are inconsistent.
Objectives
To study patient and tumour characteristics, incidence trends and survival outcomes of desmoplastic melanoma in comparison with other melanoma subtypes using data from the population‐based Swedish Melanoma Registry (SweMR).
Methods
Clinicopathological variables were obtained from SweMR, for patients diagnosed with invasive cutaneous melanomas diagnosed in Sweden from 2009 to 2022. Incidence rates of DM per 100,000 inhabitants were calculated. DM cases were identified and survival outcomes were compared across DM, superficial spreading melanoma (SSM), nodular melanoma (NM) and lentigo maligna melanoma (LMM). Survival was analysed using Kaplan–Meier and Cox regression methods.
Results
Among 48,945 invasive melanomas, 388 (0.8%) were identified as DM. The incidence ranged between 0.1 and 0.4 cases per 100,000, without a evident rise, beside a certain peak in 2019–2020 in the men. DM had compared to other melanoma subtypes the thickest primary tumours ( p < 0.001). When adjusting for baseline prognostic factors, DM patients had an improved melanoma‐specific survival (HR 0.36, 95% CI 0.26–0.49). No significant improvement in survival was observed for DM diagnosed in 2015–2022 compared to those diagnosed in 2009–2014 (adjusted HR 0.99, 95% CI 0.45–2.14), whereas other subtypes showed an improvement (adjusted HR 0.74, 95% CI 0.68–0.80).
Conclusions
In contrast to the rising incidence of other melanoma subtypes, the incidence of DM has remained more stable over recent years. Despite presenting with adverse prognostic features, survival from DM is superior when adjusting for these factors. However, the introduction of anti‐PD‐1 therapy has not significantly improved survival for DM patients.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
- Regional Cancer Center Southeast Sweden and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
- Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
- Dermatology and Venereology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Sciences, Surgery, Lund University, Lund, Sweden.
ORCID profiles: Yodit Girmay, Jan Lapins, Hildur Helgadottir
Funding
- Cancer Research Funds of Radiumhemmet
- Region Stockholm
- Cancerfonden
Cite
APA
Girmay, Y., Portelli, F., Mikiver, R., Lapins, J., Isaksson, K., & Helgadottir, H. (2026). Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20522
Vancouver
Girmay Y, Portelli F, Mikiver R, Lapins J, Isaksson K, Helgadottir H. Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.20522
BibTeX
@article{Girmay2026,
author = {Girmay, Yodit and Portelli, Francesca and Mikiver, Rasmus and Lapins, Jan and Isaksson, Karolin and Helgadottir, Hildur},
title = {Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
doi = {10.1111/jdv.20522}
}
EUVIMED